PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 17 | 111-129
Article title

Anticancer Activities of Ferrous and Ferric Ions in Progression, Proliferation, Angiogenesis, Invasion and Metastasis against Cancer and Tumor Cells

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
The process of ferroptotic death is characterized by the overwhelming, iron-depending accumulation of lethal lipid ROS. Unlike other forms of apoptotic and non-apoptotic death, this requirement for ROS accumulation appears to be universal. Redox cycling is a characteristic of transition metals such as iron (Ferritin Fe3+ ⇄ Ferrous Fe2+). Iron via the Fenton reaction can exacerbate the consequences of hydrogen peroxide (H2O2) production, leading to the generation of hydroxyl radicals. The superoxide ion can participate in regenerating ferrous iron that is required for the Fenton reaction. An excess of iron is toxic due to its ability to engage in redox cycling and promote free radical formation. Super oxide anion generation; O2 → ・O2-. Hydrogen peroxide production; ・O2- + 2H+ + e- → H2O2. Haber-Weiss reaction; H2O2 + O2- → ・OH + OH- + O2. Fenton reaction; Fe2+ + H2O2 → Fe3+ + OH- + ・OH. Reduction to Fe(Ⅱ); Fe3+ + ・O2- → Fe2+ + O2. Ferritin is stable in iron-rich conditions, whereas it is rapidly degraded under conditions of iron starvation and ferritin degradation can be led. New blood vessel formation in angiogenesis is fundamental to tumor growth, invasion, and metastatic dissemination. Iron deficiency will lead to the dysfunction of immune system, metabolic disorders, myasthenia and anemia, whereas, excess iron also damages several vital organs. Thus, iron is essential for multiple cell functions, but is also potentially deleterious reasons of its ability to generate free oxygen radicals, iron balance by continuously recycling and reusing cellular iron, storage in ferritin, and export through ferroportin protecting cells from free iron toxicity. However. the exact molecular mechanism involved on iron imbalance in development for tumor cells and the iron overload-mediated induction of apoptosis are required to be explored in future.
Year
Volume
17
Pages
111-129
Physical description
Contributors
author
  • 2-3-6, Saido, Midori-ku, Saitama-shi, Saitama Prefecture 〒336-0907, Japan
References
  • [1] Jian Wang and Kostas Pantopoulos, Regulation of cellular iron metabolism, Biovhem. J. 434 (2011) 365-381.
  • [2] H.Ludwig, R.Evstatiev, G.Kornek, et al, Iron metabolism and iron supplementation in cancer patients, Wient klinische Wochenschrift, 127 (2015) 907-919.
  • [3] Christine C. Winterbourn, Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicology Letters 82-83 (1995) 969-974.
  • [4] Caiguo Zhang and Fan Zhang, Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities, Protein Cell, 6(2) (2015) 88-100.
  • [5] Michael John Kerins and Aikseng Ooi, The roles of NRF2 in modulating cellular iron homeostasis, Antioxidants & Redox Signaling, 00 (2017) 1-19. DOI:101089/ars.2017.7176.
  • [6] Shinya Toyokuni, Role of iron in carcinogenesis: Cancer as a ferrotoxic disease, Cancer Sci. 100(1) (2009) 9-16.
  • [7] Xiang Xue and Yatrik M. Shah, Intestinal homeostasis and colon tumorigenesis, Nutrients, 5 (2013) 2333-2351.
  • [8] H.C. Hacher, R.N. Singh, F.M. Torti, and S.V. Torti, Synthetic and natural iron chelators:therapeutic potential and clinical use, Future Med Chem, 1(9) (2009) 1-17.
  • [9] S.V. Torti and F.M. Torti, Iron and cancer: more ore to be mined, Nat Rev Cancer, 13(5) (2013) 342-355.
  • [10] S.J. Dixon, K.M. Lemberg, M.R. Lamprecht et al, Ferroptosis: An ion-dependent form of non-apoptotic cell death, Cell. 149(5) May 25 (2012) 1060-1072.
  • [11] Christofferson DE, Yuan J., Necroptosis as an alternative form of programmed cell death. Current Opinion in Cell Biology 22 (2010) 263-268.
  • [12] JP. Kehrer, The Haber-Weiss reaction and mechanism of toxicity, Toxicology, 149, Issue 1 (2000) 43-50.
  • [13] Suzy V. Torti and Frank M. Torti, Cellular iron metabolism in prognosis and therapy of breast cancer, Crit Rev Oncog. 18(5) (2013) 435-448.
  • [14] S.H. Holt, M. Darash-Yahana, Yang Sung Sohn, et al, Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells, J. Cell Sci. 129 (2015) 155-165.
  • [15] S. Ma, R.F. Dielschneider, E.S.Henson et al, Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells, Plos One, August 21 (2017) 1-14.
  • [16] Min Pang BS and James R.Connor, Role of ferritin in cancer biology, Cancer Sci. & Therapy, 7(5) (2015) 155-160.
  • [17] A. Cozzi, S. Levi, B. Corsi, P. Santambrogio et al, Role of iron and ferritin in TNFα-induced apoptosis in HeLa cells. FEBS Letters 537 (2003) 187-192.
  • [18] T.R. Daniels, E. Bernabeu, J.A. Rodriguez et al, Transferrin receptors and the targeted delivery of therapeutic agennts against cancer, Biochmi Biophys Acta. 1820(3) (2012) 291-317.
  • [19] J.C. Kwok and D.R. Richardson, Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: Inhibition of the ferritin iron mobilization pathway, Molecular Pharmacology 63(4) (2003) 849-861.
  • [20] Nai-Di Yang, Shi-Hao Tan, Shukie Ng et al, Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin, J. Biological Chemistry 289(48) (2014) 33425-33441.
  • [21] Benjaporn Buranrat and James R. Connor, Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death, Oncology Reports 34 (2015) 2790-2796.
  • [22] N. Qing, T. De Marchi, A.M. Timmermans et al, Ferritin heavy chain in triple negative breast cancer, Molecular & Cellular Proteomics, 13(7 )(2014) 1814-1826
  • [23] N. Lobello, F. Biamonte, M.E. Pisanu, et al, Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition, Oncotarget, 7(38) (2016) 62019-62033.
  • [24] R. Luria-Perez, G. Helguera, J. A. Rodriguez, Antibody-mediated targeting of the transferrin receptor in cancer cells, Bol Med Hosp Infant Mex. 73(6) (2016) 372-379.
  • [25] W.Wang, M.A.Knovich, L.G.Coffman et al, Serum ferritin: Past, Present and Future, Biochim Biophys Acta. 1800(8) (2010) 760-769.
  • [26] D. Kaur, F. Yantiri, S. Rajagopalan et al, Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson’s disease, Neuron, 37(March 27) (2003) 899-909.
  • [27] C.E. Cooper, G.R. Lynagh, K.P. Hoyes et al, The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase, J. Biological Chemistry, 271(34) (1996) 20291-20299.
  • [28] V. Corce, S.G. Gouin, S. Renaud et al, Recent advances in cancer treatment by iron chelators, Bioorganic and Medical Chemistry Letters, 26 (2016) 251-256.
  • [29] S.H. Davoodi, Y. Jamshidi-Naeini, S. Esmae ili et al, The dual nature of iron in relation to cancer: A review. Iran J Cancer Prev. 9(6) (2016) 1-15.
  • [30] J. Jian, Q. Yang, J. Dai, J. Eckard et al, Effects of iron deficiency and overload on angiogenesis and oxidative stress ― A potential dual role for iron in breast cancer, Free Radic Biol Med. 50(7) (2011) 841-847.
  • [31] Xi Huang, Does iron have a role in breast cancer? Lancer Oncol. 9(8) (2008) 803-807.
  • [32] E. Poggiali, E. Cassinerio, L. Znnaboni, M.D. Cappellini, An update on iron chelation therapy, Blood Transfus 10 (2012) 411-422.
  • [33] E.R. Anderson, M. Taylor, X. Xue et al, Instestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia, PNAS 26 (2013) E4922-4930.
  • [34] Dong-Mei Zou, MD, Dong-Dong Rong, Hong Zhao et al, Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload, Clinical Case Report, Medicine OPEN 1-4, 96 (2017) 52-55.
  • [35] E. Balogh, E. Tolnai, B. Nagy et al, Iron overload inhibits osteogenic commitment and differentiation of mesenchymal stem cells via the induction of ferritin, Biochimica et Biophysica Acta 1862 (2016) 1640-1649.
  • [36] A. Kuban-Jankowska, K.K. Sahu, M. Gorska-Ponikowska et al, Inhibitory activity of iron chelators ATA and DFO on MCF-7 breast cancer cells and phosphatases PTP1B and SHP2. Anticancer Research 37 (2017) 4799-4806.
  • [37] Clara Camaschella, Iron and hepcidin: a story of recycling and balance, Hematology Am Soc Hematol Educ Program. (2013) 1-8. doi: 10.1182/asheducation-2013.1.1
  • [38] D.A. Green, W.E. Antholine, S.J. Wong et al, Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazine class, Clin Cancer Res. 7(11) (2001) 3574-3579.
  • [39] Florian R. Greten, The irony of tumor-induced inflammation, Cell Metabolism, 13 (2016) 368-369.
  • [40] Douglas B. Kell and Etheresia Pretorius, Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells, Metallomics, 6 (2014) 748-773.
  • [41] John W. Adamson, The anemia of inflammation/malignancy: Mechanisms and management, American Society of Hematology, 2008(1)(2008)159-165.
  • [42] Malianne Wessling-Resnick, Iron homeostasis and the inflammatory response, Annu Rev Nutr. 30 (2010) 105-122.
  • [43] Devika Kir, Manju Sauja, Shrey Modi et al, Cell-permeable iron inhibit vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis, Oncotarget, 7(40) (2016) 65348-65369.
  • [44] L.G. Goffman, D. Parsonage, R. D’Agostino, Jr. et al, Regulatory effects of ferritin on angiogenesis, PNAS 106(2) (2009) 570-575.
  • [45] J. Eckard, J. Dai, J. Wu et al, Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis, Cancer Cell International 10, 28 (2010) 1-11
  • [46] H. Cho, H-Y. Lee, D-R. Ahn, et al, Baicalein induces functional hypoxia-inducible factor-1α and angiogenesis, Molecular Pharmacology 74(1) (2008) 70-81.
  • [47] Mehdi Rajabi and Shaker A.Mousa, The role of angiogenesis in cancer treatment, Biomedicines 5, 34 (2017) 1-12.
  • [48] Gang Niu and Xiaoyuan Chen, Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy, Curr Drug Targets, 11(8) (2010) 1000-1017.
  • [49] Bahar Cat, Dominik Stuhlmann, Holger Steinbrenner et al, Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species, J Cell Sci. 119 (2006) 2727-2738.
  • [50] W.G. Jiang, A.J. Sanders, M. Katoh, et al, Tissue invasion and metastasis: Molecular, biological and clinical perspectives, Seminars in cancer biology, 35 (2015) 5244-5275.
  • [51] Zaklina Kovacevic, Dong Fu, Des R. Richardson, The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets, Biochimica et Biophysica Acta, 1783 (2008) 1981-1992.
  • [52] Z. Kovacevic, Sherin Chikhani, D.B. Lovejoy et al, Novel thiosemicarbazone iron chelators induced up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer, Molecular Pharmacology 80(4) (2011) 598-609.
  • [53] J. Wang, D.Yin, C.Xie, T. Zheng et al, The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway, Oncotarget 5(18) (2014) 8478
  • [54] D.H. Manz, N.L. Bianchette, B.T. Paul et al, Iron and cancer: recent insights. Ann N Y Acad Sci. 1368(1) (2016) 149-161.
  • [55] J.A. Bertout, A.J. Majmundar, J.D. Gordan, J.C. Lam et al, HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses, PNAS 106(34) (2009) 14391-14396.
  • [56] X. Sun, Z. Ou, M. Xie, R. Kang et al, HSPB1 as a novel regulator of ferroptotic cancer cell death, Oncogene 34(45) (2015) 5617-5625.
  • [57] Kyle Bauckman, Edward Haller, Nicholas Taran et al, Iron alters cell survival in a mitochondria-dependent pathway in ovarian cancer cell, Biochem. J. 466 (2015) 401-413.
  • [58] JCS Ho, A Nadeem, A Rydstrorm, M. Puthia and C. Svanborg, Targeting of nucleotide-binding proteins by HAMLET a conserved tumor cell death mechanism, Oncogene (2015) 1-11.
  • [59] Fan Yang, Yuan Li, Gege Yan, Tianyi Liu et al, Inhibition of iron overload-induced apoptosis and necrosis of bone marrow mesenchymal stem cells by melatonin, Oncotarget 8(19) (2017) 31626-31637.
  • [60] John Porter, and Maciej Garbowski, Consequences and management of iron overload in sickle cell disease, American Society of Hematology 2013 (2013) 447-455.
  • [61] Q. Tian, S. Wu, Z. Dai, J. Yang et al, Iron overload induced death of osteoblasts in vitro: improvement of the mitochondrial apoptotic pathway, Peer J 2016 (2016) 1-27 DOI 10.7717/peerj.2611.
  • [62] Qi Xu, Anumantha G. Kanthasamy, Huajun Jin, and Manju B. Reddy, Hepcidin plays a key role in 6-OHDA induces iron overload and apoptotic cell death in a cell culture model of Parkinson’s disease, Parkinson’s Disease 2016 (2016) 1-7.
  • [63] Gadah I. Al-Basher, Green tea activity and iron overload induced molecular fibrogenesis of rat liver, Saudi Journal of Biological Sciences, 2017(1) (2017) 1-9.
  • [64] Igor P Pogribny, Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer, Pogribny Breast Cancer Research 12(5) (2010) 314-315.
  • [65] W. Guo, S. Zhang, Y. Chen et al, An important role of the hepcidin-ferroportin sighnaling in affecting tumor growth and metastasis, Acta Biochim Biophys Sin 47(9) (2015) 703-715.
  • [66] X. Jiang, C. Zhang, S. Qi, S. Guo et al, Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress, Oncotarget, 7(51) (2016) 84893-84906.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-8be6d2e9-2f6a-4b8b-a9ff-bf30291bdd8b
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.